#ASCO25 #GU highlights day 3️⃣:
🧬ENZA-p: LuPSMA + enzalutamide improved OS & QoL in mCRPC
🔥EVOLUTION: LuPSMA + Ipi/Nivo = better rPFS but ↑ toxicity
💉BCG+Mitomycin: Similar DFS, 40% ↓ BCG use
🧪Biomarkers (PSMA PET, ctDNA) guide care
🧍♂️Focus on QoL, patient-centered outcJl3Dw